Unlock instant, AI-driven research and patent intelligence for your innovation.

3-aryloxy-3-five-membered heteroaryl-propylamine compound as well as crystal form and application thereof

A compound, heteroaryl technology, applied in the field of 3-aryloxy-3-pentaaryl-propylamine compounds

Pending Publication Date: 2020-11-17
SHANGHAI LEADO PHARMATECH CO LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Therefore, considering the current pain treatment as a clinical unmet need, and many problems of existing therapeutic drugs, there is an urgent need in this field to develop a therapeutic drug for TRP targets (especially TRPA1 targets), thereby improving The effect of disease treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 3-aryloxy-3-five-membered heteroaryl-propylamine compound as well as crystal form and application thereof
  • 3-aryloxy-3-five-membered heteroaryl-propylamine compound as well as crystal form and application thereof
  • 3-aryloxy-3-five-membered heteroaryl-propylamine compound as well as crystal form and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0451] A preferred preparation method of the hydrochloride crystal form A of the compound of formula I-1 according to the present invention comprises the steps of:

[0452] (a) After the compound of formula I-1 is mixed with ethyl acetate, hydrochloric acid is added dropwise at 5-15°C to adjust the pH of the system to 6-8, and a solid is precipitated in the reaction, and the hydrochloride crystal form of the compound of formula I-1 is obtained by filtration a.

[0453] In another preferred example, in the step (a), the reaction time is 3-8 minutes, preferably 5 minutes.

[0454] In another preferred example, in the step (a), the weight volume (kg:L) ratio of the compound of formula I-1 to the organic solvent is 0.2-2:2-30, preferably 0.4-1.0:5 -18, more preferably 0.5-0.9:8-15.

[0455] The hydrochloride crystal form A of the compound of formula I-1 described in the present invention can inhibit TRPA1.

[0456] Composition and method of application

[0457] The invention p...

Embodiment 1

[0475] (R)-7-(3-Chloro-1-(thiophen-2-yl)propoxy)benzofuran (Intermediate II-1)

[0476]

[0477] Dissolve 528 mg of (S)-3-chloro-1-(thiophen-2-yl)propan-1-ol, 400 mg of 7-hydroxybenzofuran and 862 mg of triphenylphosphine in 30 mL of anhydrous THF 667 mg of diisopropyl azodicarboxylate was slowly added dropwise to the system under ice-bath conditions, and after the addition was completed, the system was transferred to room temperature for overnight reaction. After the reaction was completed, the system was spin-dried directly, and the residue was separated and purified by column chromatography to obtain Intermediate II-1 compound, 685 mg of a colorless oil, with a yield of 78.46%.

[0478] 1 H NMR (500MHz, CDCl 3)δ7.62(t, J=3.2Hz, 1H), 7.41(dd, J=1.8, 0.6Hz, 1H), 7.24(dt, J=8.1, 1.8Hz, 1H), 7.15–7.11(m, 1H ), 6.91(d, J=7.7Hz, 1H), 6.77(dd, J=8.0, 2.2Hz, 1H), 6.35(d, J=3.3Hz, 1H), 6.33(dd, J=3.3, 1.9Hz ,1H),5.75(dd,J=8.4,5.1Hz,1H),3.93(dd,J=11.1,8.2,5.4Hz,1H),3.77–3.70(m...

Embodiment 2

[0480] (R)-3-(benzofuran-7-yloxy)-N-methyl-3-(thiophen-2-yl)propan-1-amine (compound I-1)

[0481]

[0482] 685 mg of intermediate II-1 was dissolved in a saturated solution of sodium iodide in acetone and refluxed overnight. After the reaction, the solvent was spin-dried, water was added to the system, extracted three times with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, the residue was dissolved in 30 ml of tetrahydrofuran solution, and 3 ml of 40 % methylamine aqueous solution and reacted overnight. After the reaction, the solvent was spin-dried, and aqueous sodium hydroxide solution was added to the system, extracted three times with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was separated by column chromatography (methanol / dichloro Methane=1:15), to obtain compound I-1, 336 mg of colorless oil, yield 49.97%.

[0483] 1H NMR (500M...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a 3-aryloxy-3-five-membered heteroaryl-propylamine compound as well as a crystal form and application thereof. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, the compound having a structure of Formula I. The compound, or the pharmaceutically acceptable salt thereof, or the prodrug thereof provided by the invention has an excellent inhibition effect on transient receptor potential channel protein (TPR), and has a good treatment effect on diseases related to the transient receptor potential channel protein.

Description

technical field [0001] The present invention relates to the fields of medicinal chemistry and pharmacotherapeutics, in particular to a 3-aryloxy-3-penta-membered heteroaryl-propylamine compound and its crystal form and application. Background technique [0002] Pain, known as the fifth vital sign, is a warning signal of damage to body tissues. Pain is one of the most common reasons for patients to seek medical treatment. According to the duration, it can be divided into acute pain (sharp onset, short duration, or continuous state) and chronic pain (slow onset or transformed from acute pain, long duration, It can also be intermittent, and many chronic pains cannot find obvious damage). Acute pain is mostly nociceptive pain caused by tissue trauma, including postoperative pain, trauma, burn pain, labor pain, angina, biliary colic, renal colic and other visceral pain, fracture pain, toothache, cancer pain, etc. Surgical and post-traumatic pain is the most common and most urge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D409/12C07D333/20C07D307/86A61P29/00A61P25/08A61P11/00A61P17/04A61P13/02A61P1/04A61P25/04A61P25/06A61P19/02A61K31/381A61K31/343
CPCC07D409/12C07D333/20C07D307/86A61P29/00A61P25/08A61P11/00A61P17/04A61P13/02A61P1/04A61P25/04A61P25/06A61P19/02C07B2200/13C07B2200/07
Inventor 王友鑫张玲玲丁强
Owner SHANGHAI LEADO PHARMATECH CO LTD